Shares of DexCom Inc. rallied 7.22% to $77.98 Thursday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index falling 0.51% to 7,533.77 and Dow Jones ...

DexCom, Inc. DXCM is well positioned for growth in the coming quarters, supported by the significant potential of the ...

DexCom (NASDAQ:DXCM) stock saw a notable increase of 16% on Friday following the announcement of its Q1 earnings and a share buyback program. The company’s first-quarter sales hit $1.04 billion, ...

Shares of DexCom Inc. DXCM shed 1.71% to $76.65 Friday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index SPX falling 1.01% to 7,457.69 and Dow Jones ...

It's been a tough year for DexCom (NASDAQ: DXCM), whose stock price is down 25% since the start of 2025. It's a surprising performance, given that the overall stock market has been doing well; you ...

DexCom (DXCM) stock has been in focus after Investor Day communications that many fund managers say improved sentiment, ...

Shares of diabetes management equipment provider DexCom (NASDAQ: DXCM) had tumbled 17% by 11:15 a.m. ET on Friday, according to data provided by S&P Global Market Intelligence. The culprit was the ...

DexCom is expected to announce its second-quarter earnings soon, and Wall Street expects the company’s EPS to increase by a ...

DexCom DXCM recently announced that it has received FDA clearance for its CGM-integrated basal insulin dosing optimizer, Dexcom Smart Basal, for use by adults with Type 2 diabetes on glargine U-100 ...

On the other hand, DexCom is a pure-play CGM company whose target market consists mainly of people with Type 1 and Type 2 diabetes using insulin therapy, as well as certain non-insulin users who ...

DexCom's growth rate has been accelerating for multiple quarters, and recently came in at around 22%. A rise in GLP-1 drugs has some investors concerned that DexCom's growth opportunities may be ...